X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Brian Newell

Brian Newell is Deputy Vice President of Public Affairs at PhRMA and serves as lead spokesperson for national media. Before joining PhRMA in 2020, he served as managing director of strategic communications for the Biotechnology Innovation Organization (BIO). Prior to BIO, Brian worked on Capitol Hill for ten years, including roles on the Education and Workforce Committee, the House Republican Conference and the Ways and Means Committee. Brian graduated with a BA in Political Science from the University of Maine, his home state. He enjoys spending time with his wife and two children – especially summer vacations on the lake in Maine.

Recent Posts

What is Kaiser Family Foundation up to?

By Brian Newell  |    October 12, 2021
For years, Kaiser Family Foundation (Kaiser) has reminded lawmakers that Americans are opposed to government “negotiation” in drug pricing should it lead to less access to medicines and destroy...   Read More

Industry leaders discuss the impact of the drug pricing debate

By Brian Newell  |    September 23, 2021
This month, PhRMA hosted a media briefing with leaders within the biopharmaceutical industry to discuss the dangers of current proposals on government price setting, while also sharing alternative...   Read More

New reports shed light on key facts about medicines and affordability

By Brian Newell  |    June 8, 2021
A recently released report by IQVIA – an independent organization specializing in health care research – provides new data showing prices for brand medicines went down last year. The report offers...   Read More

The latest misleading “poll” on drug pricing

By Brian Newell  |    January 28, 2021
When a front group for insurers and drug cost middlemen promote a poll on drug pricing, everyone’s immediate reaction should include a healthy dose of skepticism. The same is true for a poll from...   Read More

New insulin report highlights how incentives benefit middlemen, harm patients

By Brian Newell  |    January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates